This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Geron Announces Senior Management Appointments

Stocks in this article: GERN

Geron Corporation (Nasdaq:GERN) today announced the appointments of Stephen Kelsey, M.D., to Executive Vice President, Head of Research & Development and Chief Medical Officer; Jane Lebkowski, Ph.D., to Senior Vice President and Geron’s Chief Scientific Officer; and Melissa Kelly Behrs to Senior Vice President, Strategic Portfolio Management. Drs. Kelsey and Lebkowski and Ms. Behrs will report to David Greenwood, Geron’s President and Chief Executive Officer.

“By appointing Dr. Kelsey, Dr. Lebkowski and Ms. Behrs to these roles with functional responsibilities across Geron’s programs, we leverage their accumulated expertise and distinctive capabilities to direct the science and clinical programs, and to integrate the strategic business plan,” said Mr. Greenwood. “Steve has a proven track record in clinical development and leadership of research programs and in this capacity will manage to meet our defined goals within defined timeframes. Under Jane’s leadership, the Geron team advanced hESC technology from initial discovery to a first product in the clinic, with every step being an inventive step. Geron was founded on innovative and excellent science, including telomerase and hESCs, leading to our products in the clinic today. We want to maintain this tradition internally and build on our external network of key thought leaders. Finally, it is imperative that a technology rich company like Geron maintains the product development focus with clearly defined strategies to progress products into and through clinical trials. Melissa has well demonstrated capabilities to provide this leadership.”

Dr. Kelsey joined Geron in 2009 as Executive Vice President and Chief Medical Officer, Oncology. Previously, he held senior positions at Genentech and Pharmacia (Sugen, Inc.), where he was responsible for a broad range of development programs spanning pre-Phase 1 through marketed products. Dr. Kelsey held positions as a clinician and researcher in hematology/oncology at St. Bartholomews and the Royal London School of Medicine and Dentistry. He earned his M.D. in the U.K. at the University of Birmingham.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,317.95 -98.90 -0.57%
S&P 500 2,008.45 -12.80 -0.63%
NASDAQ 4,663.1390 -20.2680 -0.43%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs